

**BIOCON GROUP**

**FACT SHEET**

**June - 2024**

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			(Rs. Crores)
<b>Particulars</b>	<b>Q1 FY 25</b>	<b>Q1 FY 24</b>	<b>Variance %</b>
<b><u>INCOME</u></b>			
Generics	659	700	-6%
Biosimilars	2,083	2,015	3%
Novel Biologics	-	-	0%
Research services	790	808	-2%
Inter-segment	(100)	(101)	-1%
<b>Revenue from operations #</b>	<b>3,433</b>	<b>3,423</b>	<b>0%</b>
Other income	1,134	94	1113%
<b>TOTAL REVENUE</b>	<b>4,567</b>	<b>3,516</b>	<b>30%</b>
<b><u>EXPENDITURE</u></b>			
Material & Power costs	1,276	1,324	-4%
Staff costs	702	520	35%
Research & Development expenses*	228	315	-28%
Other expenses	606	550	10%
<b>Manufacturing, staff &amp; other expenses</b>	<b>2,812</b>	<b>2,708</b>	<b>4%</b>
<b>EBITDA</b>	<b>1,755</b>	<b>808</b>	<b>117%</b>
Interest & Finance charges	236	233	1%
Depreciation & Amortisation	405	358	13%
Share of loss / (profit) in JV / Associate, net	-	33	-100%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>1,114</b>	<b>184</b>	<b>506%</b>
Exceptional item	32	-	-
<b>PBT</b>	<b>1,146</b>	<b>184</b>	<b>524%</b>
Taxes	273	35	684%
Taxes on exceptional item	11	-	100%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>862</b>	<b>149</b>	<b>479%</b>
Minority interest	193	48	305%
Minority interest on exceptional item	10	-	100%
<b>NET PROFIT FOR THE PERIOD</b>	<b>660</b>	<b>101</b>	<b>551%</b>
<b>EPS Rs.</b>	<b>5.5</b>	<b>0.8</b>	
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>			
Exceptional item, net of taxes	12	-	100%
<b>NET PROFIT FOR THE PERIOD</b>	<b>660</b>	<b>101</b>	<b>551%</b>
<i># Licensing Income</i>	6	167	
<i>* Gross Research &amp; Development expenses</i>	228	324	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	Q1 FY 25	Q4 FY 24	Variance %
<b>INCOME</b>			
Generics	659	719	-8%
Biosimilars	2,083	2,358	-12%
Research services	790	917	-14%
Inter-segment	(100)	(76)	31%
<b>Revenue from operations #</b>	<b>3,433</b>	<b>3,917</b>	<b>-12%</b>
Other income	1,134	49	2239%
<b>TOTAL REVENUE</b>	<b>4,567</b>	<b>3,966</b>	<b>15%</b>
<b>EXPENDITURE</b>			
Material & Power costs	1,276	1,417	-10%
Staff costs	702	532	32%
Research & Development expenses*	228	246	-7%
Other expenses	606	806	-25%
<b>Manufacturing, staff &amp; other expenses</b>	<b>2,812</b>	<b>3,001</b>	<b>-6%</b>
<b>EBITDA</b>	<b>1,755</b>	<b>964</b>	<b>82%</b>
Interest & Finance charges	236	227	4%
Depreciation & Amortisation	405	407	0%
Share of loss / (profit) in JV / Associate, net	-	3	-100%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>1,114</b>	<b>328</b>	<b>240%</b>
Exceptional item, Net	32	(9)	-100%
<b>PBT</b>	<b>1,146</b>	<b>319</b>	<b>259%</b>
Taxes	273	98	180%
Taxes on exceptional item	11	(2)	-820%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>862</b>	<b>223</b>	<b>287%</b>
Minority interest	193	87	121%
Minority interest on exceptional item	10	-	-
<b>NET PROFIT FOR THE PERIOD</b>	<b>660</b>	<b>136</b>	<b>386%</b>
<b>EPS Rs.</b>	<b>5.5</b>	<b>1.1</b>	
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>			
	648	144	351%
Exceptional item	12	(8)	
<b>NET PROFIT FOR THE PERIOD</b>	<b>660</b>	<b>136</b>	<b>386%</b>
<i># Licensing Income</i>	6	15	
<i>* Gross Research &amp; Development expenses</i>	228	228	

**BIOCON LIMITED (CONSOLIDATED)**  
**BALANCE SHEET**

(Rs Crores)

Particulars	Jun 30, 2024	Mar 31, 2024
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	7,368	7,418
(b) Capital work-in-progress	4,168	3,985
(c) Right-of-use assets	597	575
(d) Goodwill	16,378	16,372
(e) Other intangible assets	6,136	6,279
(f) Intangible assets under development	4,101	4,008
(g) Financial assets		
Investments	660	684
Derivative assets	256	266
Other financial assets	157	147
(i) Income tax asset, net	434	413
(j) Deferred tax asset, net	282	317
(k) Other non-current assets	480	428
<b>Non-current assets</b>	<b>41,017</b>	<b>40,892</b>
<b>Current assets</b>		
(a) Inventories	5,037	4,944
(b) Financial assets		
Investments	814	316
Trade receivables	5,635	6,231
Cash and cash equivalents	1,357	1,234
Other bank balances	562	1,025
Derivative assets	179	138
Other financial assets	275	577
(c) Other current assets	795	715
<b>Current assets</b>	<b>14,654</b>	<b>15,180</b>
<b>TOTAL - ASSETS</b>	<b>55,671</b>	<b>56,072</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	600	600
(b) Other equity	19,898	19,183
<b>Equity attributable to owners of the Company</b>	<b>20,498</b>	<b>19,783</b>
Non-controlling interests	5,715	5,491
<b>Total Equity</b>	<b>26,213</b>	<b>25,274</b>
<b>Non-current liabilities</b>		
(a) Financial liabilities		
Borrowings	12,454	12,932
Lease liabilities	472	492
Other financial liabilities	1,115	1,073
(b) Other non-current liabilities	346	311
(c) Provisions	235	238
(d) Deferred tax liability, net	397	392
<b>Non-current liabilities</b>	<b>15,019</b>	<b>15,438</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
Borrowings	3,362	2,797
Lease liabilities	99	55
Trade payables	5,661	6,272
Derivative liabilities	-	1
Other financial liabilities	4,130	5,001
(b) Other current liabilities	701	777
(c) Provisions	197	180
(d) Income tax liability, net	289	277
<b>Current liabilities</b>	<b>14,439</b>	<b>15,360</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>55,671</b>	<b>56,072</b>